Get the Stockscreener App
3.26
1.81%
-0.06
Prelude Therapeutics Inc stock is traded at $3.26, with a volume of 479.27K.
It is down -1.81% in the last 24 hours and down -27.07% over the past month.
Prelude Therapeutics Incorp is a precision oncology company developing medicines in areas of high unmet need for cancer patients. Its pipeline features selective KAT6A degraders and mutant selective JAK2V617F JH2 inhibitors, new approaches to clinically validated targets with transformative potential for patients. The company is also leveraging its expertise in targeted protein degradation to discover and develop next-generation degrader antibody conjugates (DACs) with novel payloads.
See More
Previous Close:
$3.32
Open:
$3.32
24h Volume:
479.27K
Relative Volume:
1.15
Market Cap:
$260.16M
Revenue:
$16.72M
Net Income/Loss:
$-77.80M
P/E Ratio:
-3.0833
EPS:
-1.0573
Net Cash Flow:
$-43.78M
1W Performance:
-16.20%
1M Performance:
-27.07%
6M Performance:
-26.41%
1Y Performance:
+148.85%
1-Day Range:
$3.18
$3.41
1-Week Range:
$3.18
$3.94
52-Week Range:
$1.16
$6.83
Prelude Therapeutics Inc Stock (PRLD) Company Profile
Name
Prelude Therapeutics Inc
Sector
Industry
Phone
(302) 467-1280
Address
175 INNOVATION BOULEVARD, WILMINGTON
Compare PRLD vs VRTX, MRNA, REGN, ARGX, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
PRLD
Prelude Therapeutics Inc
|
3.26 | 260.16M | 16.72M | -77.80M | -43.78M | -1.0573 |
VRTX
Vertex Pharmaceuticals Inc
|
499.74 | 126.66B | 12.34B | 4.34B | 3.71B | 16.87 |
MRNA
Moderna Inc
|
218.01 | 87.04B | 2.23B | -3.19B | -1.60B | -8.1462 |
REGN
Regeneron Pharmaceuticals Inc
|
790.74 | 81.41B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
819.14 | 51.51B | 4.16B | 1.29B | 734.26M | 19.58 |
ONC
Beone Medicines Ltd Adr
|
369.06 | 41.75B | 5.76B | 514.49M | 1.10B | 4.4813 |
Prelude Therapeutics Inc Stock (PRLD) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Sep-17-26 | Initiated | JP Morgan | Overweight |
| May-04-26 | Initiated | D. Boral Capital | Buy |
| Sep-19-24 | Upgrade | H.C. Wainwright | Neutral → Buy |
| Jun-20-24 | Downgrade | Barclays | Equal Weight → Underweight |
| Mar-13-24 | Initiated | JMP Securities | Mkt Outperform |
| Feb-20-24 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Dec-19-23 | Downgrade | Morgan Stanley | Equal-Weight → Underweight |
| Nov-21-22 | Downgrade | BofA Securities | Neutral → Underperform |
| Sep-09-22 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Jul-29-22 | Initiated | Jefferies | Buy |
| Mar-15-22 | Downgrade | BofA Securities | Buy → Neutral |
| Feb-28-22 | Downgrade | Barclays | Overweight → Equal Weight |
| Oct-08-21 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Jul-27-21 | Upgrade | BofA Securities | Neutral → Buy |
| Apr-26-21 | Initiated | H.C. Wainwright | Buy |
| Mar-09-21 | Initiated | Barclays | Overweight |
| Nov-20-20 | Downgrade | BofA Securities | Buy → Neutral |
| Oct-20-20 | Initiated | BofA Securities | Buy |
| Oct-20-20 | Initiated | Goldman | Neutral |
| Oct-20-20 | Initiated | Morgan Stanley | Equal-Weight |
View All
Prelude Therapeutics Inc Stock (PRLD) Latest News
H.C. Wainwright reiterates Prelude Therapeutics stock rating at buy By Investing.com - Investing.com Canada
Citizens reiterates Prelude Therapeutics stock rating on Lilly deal By Investing.com - Investing.com UK
Wainwright targets Prelude Therapeutics stock at USD 8.00 - ad-hoc-news.de
Prelude Therapeutics Teams Up With Lilly To Test Experimental Breast Cancer Drug In Phase 1 Trial - Yahoo Finance
Lilly will supply two drugs for Prelude's planned breast cancer trial. - Stock Titan
Prelude Announces Clinical Trial Collaboration and Supply Agreement with Lilly to Evaluate KAT6A Selective Degrader PRT13722 in Combination with Verzenio® and Inluriyo® in Patients with HR+/HER2- Breast Cancer - GlobeNewswire
Prelude Therapeutics stock gains 2.72 percent as targets stay high - AD HOC NEWS
Prelude Therapeutics stock falls 9.9 percent despite FDA progress - AD HOC NEWS
Prelude Therapeutics Incorporated(NasdaqGS: PRLD) added to S&P Global BMI Index - marketscreener.com
Prelude Therapeutics stock gains as FDA clears new breast cancer drug trial - AD HOC NEWS
Prelude Therapeutics at H.C. Wainwright conference: pipeline gains momentum By Investing.com - Investing.com Canada
Prelude Wins FDA Clearance to Move Breast Cancer Drug to Trial - MyChesCo
Prelude Therapeutics to Participate in the H.C. Wainwright 28th Annual Global Investment Conference - The Manila Times
Four executives will join Prelude’s fireside chat Sept. 16 - Stock Titan
Prelude Therapeutics to Participate in the H.C. Wainwright 28th Annual Global Investment Conference - GlobeNewswire
Prelude Therapeutics to Participate in the H.C. Wainwright 28th Annual Global Investment Conference - Yahoo Finance
Prelude Therapeutics Receives FDA Clearance for New Drug Clinical Trial - Intellectia AI
Prelude Therapeutics (PRLD) Gains FDA Nod for Phase 1 Trial in B - GuruFocus
Prelude Therapeutics Cleared by FDA for Phase 1 Breast Cancer Drug Trial - marketscreener.com
Prelude gets FDA clearance for breast cancer drug trial - Investing.com
Prelude Therapeutics receives FDA clearance for PRT13722 IND application - TipRanks
Prelude gets FDA clearance for breast cancer drug trial By Investing.com - Investing.com India
Prelude gets FDA clearance for breast cancer drug trial By Investing.com - Investing.com UK
Prelude Therapeutics Receives FDA Clearance of - GlobeNewswire
Prelude Therapeutics Receives FDA Clearance of Investigational New Drug (IND) Application for PRT13722, Its First-in-Class Oral KAT6A Selective Degrader - Yahoo Finance
FDA clears first human study of a breast cancer drug candidate. Prelude expects enrollment in Q4 2026. - Stock Titan
Prelude Therapeutics Cleared by FDA for Phase 1 Breast Cancer Drug Trial - Yahoo Finance
Neuraptive Therapeutics, Inc. Announces Key Org… | UNI India - uniindia.com
Prelude Therapeutics: A Prognosis After Year Long Rally (NASDAQ:PRLD) - Seeking Alpha
Prelude Therapeutics (NASDAQ:PRLD) Reaches New 1-Year HighStill a Buy? - MarketBeat
Prelude Therapeutics (NASDAQ:PRLD) Shares Up 9.3%Time to Buy? - MarketBeat
12 Health Care Stocks Moving In Thursday's Intraday Session - Benzinga
Prelude Therapeutics Number of Employees 2026 | Employee Count & Headcount Data - Revelio Labs
Prelude Therapeutics Hits New 52-Week High of $5.91, Reflecting Strong Growth - MarketsMojo
Prelude Therapeutics Incorporated reports results for the quarter ended June 30Earnings Summary - TradingView
Prelude Therapeutics Incorporated (NASDAQ:PRLD) Receives Consensus Recommendation of "Hold" from Analysts - MarketBeat
We're Not Worried About Prelude Therapeutics' (NASDAQ:PRLD) Cash Burn - Moomoo
Prelude Therapeutics (PRLD) Stock Rallies As Losses Ease But Milestones Remain Unclear - webull.com
Prelude Therapeutics (NASDAQ:PRLD) Releases Quarterly Earnings Results, Beats Estimates By $0.03 EPS - MarketBeat
Prelude Therapeutics Reports Q2 2026 Earnings Featuring First Revenue and Reduced Losses - Kalkine Media
Prelude Therapeutics Reports $13.9 Million Q2 Net Loss - Quiver Quantitative
Prelude Therapeutics reports Q2 2026 results: $5.7M revenue, $13.9M net loss, $155.2M cash - TradingView
Prelude Therapeutics reports Q2 EPS (14c), consensus (19c) - TipRanks
Prelude Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update - The Manila Times
Prelude Therapeutics Q2 revenue beats analyst expectations, net loss narrows - TradingView
Prelude Therapeutics 2Q Loss/Shr 14c >PRLD - Moomoo
Prelude Therapeutics Reports $13.9 Million Q2 Net Loss | PRLD Stock News - Quiver Quantitative
Prelude Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update - Yahoo Finance
Prelude Therapeutics (PRLD) Expected to Post Earnings on Thursday - MarketBeat
Pathos AI pads pipeline with $2.2B Alphamab deal, AZ pact - Fierce Biotech
Prelude Therapeutics Inc Stock (PRLD) Financials Data
Revenue
Net Income
Cash Flow
EPS
Prelude Therapeutics Inc Stock (PRLD) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| ORBIMED ADVISORS LLC | Director |
Apr 21 '26 |
Buy |
4.44 |
2,815,315 |
12,499,999 |
11,808,945 |
4.22%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):